Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

1,015

Participants

Timeline

Start Date

November 8, 2023

Primary Completion Date

July 17, 2024

Study Completion Date

July 17, 2024

Conditions
Pneumococcal Vaccines
Interventions
BIOLOGICAL

31 valent pneumococcal conjugate vaccine

0.5 ml dose of VAX-31 was administered into the deltoid muscle at Day 1

BIOLOGICAL

20 valent pneumococcal conjugate vaccine

0.5 ml dose of PCV20 was administered into the deltoid muscle at Day 1

Trial Locations (25)

14609

Rochester Clinical Research, Rochester

19107

DM Clinical Research - Philadelphia, Philadelphia

22911

Charlottesville Medical Research, Charlottesville

23606

Health Research of Hampton Roads, Newport News

29405

Coastal Carolina Research, North Charleston

31406

Velocity Clinical Research, Savannah, Savannah

32934

Optimal Research, Melbourne

33024

Research Centers of America, Hollywood

33351

Precision Clinical Research, Sunrise

33458

Health Awareness, Jupiter

36608

AMR Mobile, Mobile

37909

AMR Knoxville, Knoxville

44122

Velocity Clinical Research, Cleveland, Cleveland

45212

CTI Clinical Research Center, Cincinnati

48076

DM Clinical Research - Detroit, Detroit

60422

Healthcare Research Network II, LLC, Flossmoor

66219

Johnson County Clin-Trials, Lenexa

68134

Velocity Clinical Research Omaha, Omaha

76135

Benchmark Research, Fort Worth

76904

Benchmark Research, San Angelo

84107

CenExel JBR Clinical Research, Salt Lake City

85282

AMR Phoenix, Phoenix

89106

WR-CRCN, Las Vegas

08755

Cenexel AMRI, Toms River

02886

Velocity Clinical Research, Warwick

All Listed Sponsors
lead

Vaxcyte, Inc.

INDUSTRY

NCT06151288 - Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults | Biotech Hunter | Biotech Hunter